Bayesian Methods: Solving the Paradoxes of Classical Statistical Tests?

Classical statistical testing, built on the foundation of p-values and null hypothesis significance testing (NHST), has been the cornerstone of biomedical research for nearly a century. Yet persistent paradoxes and misinterpretations have led to what many call the "reproducibility crisis" in science. Bayesian methods offer a compelling alternative—and increasingly, a complement—to traditional approaches.

The Fundamental Problem with P-Values

The American Statistical Association's 2016 statement on p-values highlighted several key concerns:

P-values do not measure the probability that the null hypothesis is true

Scientific conclusions should not be based solely on whether a p-value crosses a specific threshold

Proper inference requires full reporting and transparency

The Paradox of Large Samples

One particularly troubling phenomenon: with sufficiently large samples, trivial effects become "statistically significant." A p-value of 0.001 does not indicate a clinically meaningful finding—it merely indicates a low probability of observing such results under the null hypothesis.

The Paradox of Replication

Studies show that many "significant" findings fail to replicate. This isn't necessarily due to p-hacking or publication bias alone—the misinterpretation of p-values plays a central role.

Bayesian Inference: A Different Framework

Bayesian statistics takes a fundamentally different approach:

Posterior Probability = (Likelihood × Prior Probability) / Marginal Probability

This framework allows direct probability statements about hypotheses:

"There is an 87% probability that the new treatment is superior"

"The probability that the effect size exceeds 0.5 is 0.73"

Incorporating Prior Knowledge

A key advantage: Bayesian methods naturally incorporate prior information. In drug development, this is particularly valuable:

Prior data from Phase I can inform Phase II analysis

Historical control data can strengthen small trials

Expert opinion can be formally quantified as priors

Practical Applications in Clinical Trials

Adaptive Designs

Bayesian methods excel in adaptive trial designs:

Probability of success can be calculated at interim analyses

Sample size re-estimation based on accumulating data

Go/No-go decisions can be framed probabilistically

Dose-Finding Studies

The BOIN (Bayesian Optimal Interval) design has gained regulatory acceptance:

More efficient than traditional 3+3 designs

Directly optimizes dose selection

Provides probability-based decision rules

Oncology: A Natural Fit

Oncology trials face particular challenges:

Small sample sizes in rare indications

Multiple biomarkers requiring patient stratification

High failure rates in Phase III

Bayesian methods address these through:

Borrowing strength across subgroups

Hierarchical models for basket trials

Predictive probability for trial success

Regulatory Acceptance

The FDA has shown increasing openness to Bayesian approaches:

FDA guidance documents on adaptive designs and Bayesian methods

ICH E20 (draft) on adaptive clinical trials

Bayesian designs approved in oncology (e.g., I-SPY 2)

ICH E20 and Adaptive Designs

The ICH E20 guideline (currently in draft) provides a framework for:

Prospectively planned adaptations

Statistical validity through simulation

Transparency requirements for regulators

Challenges and Limitations

Prior Specification

The choice of prior can be controversial:

Informative priors: Based on historical data, can be powerful

Non-informative priors: Allow data to speak, but may be unrealistic

Regulatory scrutiny: Skepticism about "subjective" prior choice

Computational Complexity

Modern Bayesian methods often require:

Markov Chain Monte Carlo (MCMC) simulation

Specialized software (Stan, JAGS, Bayesian software)

Longer computation times

Software Validation

Regulatory requirements demand:

Documented software validation

Reproducibility of results

Understanding of numerical approximation errors

The Way Forward: Complementary Approaches

Rather than viewing Bayesian vs. frequentist as an either/or choice, many statisticians advocate for triangulation:

Report both Bayesian and frequentist results when appropriate

Use simulation studies to validate designs under both frameworks

Let the question drive the method, not methodological preference

Conclusion

The paradoxes of classical testing—large sample significance, replication failure, misinterpretation—are not mere statistical curiosities. They have real consequences for drug development, regulatory approval, and patient care.

Bayesian methods offer a coherent framework that:

Addresses the limitations of p-values directly

Incorporates prior knowledge naturally

Provides clinically interpretable results

Enables more efficient trial designs

For biostatisticians in oncology and rare diseases, Bayesian expertise is increasingly essential. The regulatory environment is evolving to accommodate these methods—and the questions we ask deserve answers that Bayesian thinking can provide.

---

Key Points

P-values measure the probability of data under the null hypothesis—not the probability that the hypothesis is true

Bayesian methods provide direct probability statements about hypotheses

Prior information can be formally incorporated and updated with new data

FDA and ICH show increasing acceptance of Bayesian approaches in drug development

The choice of prior remains a subject of discussion and regulatory scrutiny

References

Wasserstein RL, Lazar NA. The ASA's Statement on P-Values: Context, Process, and Purpose. The American Statistician. 2016.

FDA. Adaptive Designs for Clinical Trials of Drugs and Biologics. 2019.

ICH E20. Adaptive Designs in Clinical Trials (Draft Guideline). 2025.

Berry SM, Carlin BP, Lee JJ, Müller P. Bayesian Adaptive Methods for Clinical Trials. Chapman & Hall/CRC; 2010.

Lin J, Lee CM. On the use of Bayesian methodology in clinical trials. Journal of Biopharmaceutical Statistics. 2020.